|
|
||||||||
J Thorac Cardiovasc Surg 1995;110:286-287
© 1995 Mosby, Inc.
LETTERS TO THE EDITOR |
Laboratoire de Biochimie Aa
Department d'Anesthésie et Réanimationb
Laboratoire d'Hématologiec
Service de Chirurgie Cardiothoraciqued
INSERM U 408e
Hôpital BichatClaude Bernard
Paris, France
To the Editor:
Cardiopulmonary bypass (CPB) is known to cause a systemic inflammatory response associated with an increased production of proinflammatory cytokines (interleukin-1 [IL-1], IL-6, and IL-8).
1,2 Several studies suggest that IL-10 is an important factor in the down-regulation of inflammatory responses, in particular by inhibiting in vitro proinflammatory cytokine synthesis by neutrophils (PMN) and monocytes.
3 We hypothesized that IL-10 might be produced during CPB and could represent a regulatory mechanism controlling monocyte/PMN activation in vivo. We therefore measured plasma levels of IL-10 in comparison with that of IL-6 and IL-8 in patients undergoing cardiac operations with normothermic CPB.
|
As shown in Fig 1, whereas IL-10 was undetectable in any of the plasma samples at T0 and H0, plasma IL-10 levels rose in all of the patients as early as 1 hour after the onset of CPB, peaked either at H1 or H2 (H1, 76.2 ± 26.7 pg/ml; H2, 73.5 ± 24.8 pg/ml; mean ± standard error of the mean; p = 0.01 versus H0 by Wilcoxon's matched-paired test), and decreased at H4 (23.6 ± 10 pg/ml). IL-6 and IL-8 levels peaked at 4 and 2 hours, respectively, after the onset of CPB. By contrast with the strong positive correlation observed between plasma IL-6 and IL-8 concentrations ( rho = 0.91; p = 0.02, Spearman rank order test), the level of IL-10 production was unrelated to the levels of IL-8 and IL-6.
Our results show that CPB causes the rapid and transient release of IL-10. The differences in kinetics and levels of production between IL-10 and IL-6 and IL-8 suggest different immunoregulatory mechanisms involved in their secretions. The in vivo kinetics of IL-10 during CPB are similar to those observed in experimental murine endotoxemia after lipopolysaccharide challenge.
4 These kinetics contrast with in vitro data showing that IL-10 is produced rather late after lipopolysaccharide stimulation of human monocytes
5 and suggest that other cells could be involved in the release of IL-10 in vivo. The cellular source(s) of IL-10 and the nature of stimuli leading to IL-10 release remain to be determined. We concluded that CPB induced an early IL-10 secretion. Further studies are required to determine whether this IL-10 release plays a beneficial role, by reducing the ischemia-reperfusion inflammatory response, or a detrimental role, by decreasing the cellular immune response.
References
and tumor necrosis factor production during experimental endotoxemia. Eur J Immunol 1994;24:1167-71.[Medline]This article has been cited by other articles:
![]() |
P. Corbi, M. Rahmati, A. Delwail, D. Potreau, P. Menu, J. Wijdenes, and J.-C. Lecron Circulating soluble gp130, soluble IL-6R, and IL-6 in patients undergoing cardiac surgery, with or without extracorporeal circulation Eur J Cardiothorac Surg, July 1, 2000; 18(1): 98 - 103. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |